Table of Contents Author Guidelines Submit a Manuscript
International Journal of Microbiology
Volume 2009 (2009), Article ID 879621, 9 pages
http://dx.doi.org/10.1155/2009/879621
Research Article

The Differential Gene Expression Pattern of Mycobacterium tuberculosis in Response to Capreomycin and PA-824 versus First-Line TB Drugs Reveals Stress- and PE/PPE-Related Drug Targets

Pacific Tuberculosis and Cancer Research Organization, P. O. Box 9706, Anaheim, CA 92812, USA

Received 9 November 2008; Revised 19 May 2009; Accepted 1 June 2009

Academic Editor: Vasco Azevedo

Copyright © 2009 Li M. Fu and Shu C. Tai. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Zhang and L. M. Amzel, “Tuberculosis drug targets,” Current Drug Targets, vol. 3, no. 2, pp. 131–154, 2002. View at Google Scholar
  2. J. E. Gomez and J. D. McKinney, “M. tuberculosis persistence, latency, and drug tolerance,” Tuberculosis, vol. 84, no. 1-2, pp. 29–44, 2004. View at Publisher · View at Google Scholar
  3. L. G. Wayne and C. D. Sohaskey, “Nonreplicating persistence of Mycobacterium tuberculosis,” Annual Review of Microbiology, vol. 55, pp. 139–163, 2001. View at Publisher · View at Google Scholar
  4. H. M. Blumberg, M. K. Leonard Jr., and R. M. Jasmer, “Update on the treatment of tuberculosis and latent tuberculosis infection,” Journal of the American Medical Association, vol. 293, no. 22, pp. 2776–2784, 2005. View at Publisher · View at Google Scholar
  5. W. P. Gill, N. S. Harik, M. R. Whiddon, R. P. Liao, J. E. Mittler, and D. R. Sherman, “A replication clock for Mycobacterium tuberculosis,” Nature Medicine, vol. 15, no. 2, pp. 211–214, 2009. View at Publisher · View at Google Scholar
  6. R. M. McCune Jr. and R. Tompsett, “Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique—I: the persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy,” The Journal of Experimental Medicine, vol. 104, no. 5, pp. 737–762, 1956. View at Google Scholar
  7. M. Zierski, “Capreomycin and other drugs in the treatment of pulmonary tuberculosis,” Tubercle, vol. 50, supplement, pp. 37–39, 1969. View at Google Scholar
  8. N. Rastogi, V. Labrousse, and K. S. Goh, “In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages,” Current Microbiology, vol. 33, no. 3, pp. 167–175, 1996. View at Publisher · View at Google Scholar
  9. L. Heifets, J. Simon, and V. Pham, “Capreomycin is active against non-replicating M. tuberculosis,” Annals of Clinical Microbiology and Antimicrobials, vol. 4, no. 1, p. 6, 2005. View at Publisher · View at Google Scholar
  10. C. K. Stover, P. Warrener, D. R. VanDevanter et al., “A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis,” Nature, vol. 405, no. 6789, pp. 962–966, 2000. View at Publisher · View at Google Scholar
  11. Y. Hu, A. R. M. Coates, and D. A. Mitchison, “Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis,” International Journal of Tuberculosis and Lung Disease, vol. 12, no. 1, pp. 69–73, 2008. View at Google Scholar
  12. R. Tasneen, S. Tyagi, K. Williams, J. Grosset, and E. Nuermberger, “Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 10, pp. 3664–3668, 2008. View at Publisher · View at Google Scholar
  13. C. E. Maus, B. B. Plikaytis, and T. M. Shinnick, “Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis,” Antimicrobial Agents and Chemotherapy, vol. 49, no. 2, pp. 571–577, 2005. View at Publisher · View at Google Scholar
  14. H. I. M. Boshoff, T. G. Myers, B. R. Copp, M. R. McNeil, M. A. Wilson, and C. E. Barry III, “The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action,” The Journal of Biological Chemistry, vol. 279, no. 38, pp. 40174–40184, 2004. View at Publisher · View at Google Scholar
  15. V. G. Tusher, R. Tibshirani, and G. Chu, “Significance analysis of microarrays applied to the ionizing radiation response,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 9, pp. 5116–5121, 2001. View at Publisher · View at Google Scholar
  16. S. Tavazoie, J. D. Hughes, M. J. Campbell, R. J. Cho, and G. M. Church, “Systematic determination of genetic network architecture,” Nature Genetics, vol. 22, no. 3, pp. 281–285, 1999. View at Publisher · View at Google Scholar
  17. M. Wilson, J. DeRisi, H.-H. Kristensen et al., “Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 22, pp. 12833–12838, 1999. View at Google Scholar
  18. L. M. Fu, “Exploring drug action on Mycobacterium tuberculosis using affymetrix oligonucleotide genechips,” Tuberculosis, vol. 86, no. 2, pp. 134–143, 2006. View at Publisher · View at Google Scholar
  19. J. Rengarajan, B. R. Bloom, and E. J. Rubin, “Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 23, pp. 8327–8332, 2005. View at Publisher · View at Google Scholar
  20. J. C. Betts, P. T. Lukey, L. C. Robb, R. A. McAdam, and K. Duncan, “Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling,” Molecular Microbiology, vol. 43, no. 3, pp. 717–731, 2002. View at Publisher · View at Google Scholar
  21. G. R. Stewart, L. Wernisch, R. Stabler et al., “Dissection of the heat-shock response in Mycobacterium tuberculosis using mutants and microarrays,” Microbiology, vol. 148, no. 10, pp. 3129–3138, 2002. View at Google Scholar
  22. C. M. Sassetti, D. H. Boyd, and E. J. Rubin, “Genes required for mycobacterial growth defined by high density mutagenesis,” Molecular Microbiology, vol. 48, no. 1, pp. 77–84, 2003. View at Publisher · View at Google Scholar
  23. G. Fenhalls, L. Stevens, L. Moses et al., “In situ detection of Mycobacterium tuberculosis transcripts in human lung granulomas reveals differential gene expression in necrotic lesions,” Infection and Immunity, vol. 70, no. 11, pp. 6330–6338, 2002. View at Publisher · View at Google Scholar
  24. S. T. Cole, R. Brosch, J. Parkhill et al., “Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence,” Nature, vol. 393, no. 6685, pp. 537–544, 1998. View at Publisher · View at Google Scholar
  25. J.-M. Claverie, “Computational methods for the identification of differential and coordinated gene expression,” Human Molecular Genetics, vol. 8, no. 10, pp. 1821–1832, 1999. View at Publisher · View at Google Scholar
  26. P. Hieter and M. Boguski, “Functional genomics: It's all how you read it,” Science, vol. 278, no. 5338, pp. 601–602, 1997. View at Publisher · View at Google Scholar
  27. American Thoracic Society, “CDC, Infectious Diseases Society of America. Treatment of tuberculosis,” MMWR Recommendations and Reports, vol. 52, no. RR-11, pp. 1–77, 2003. View at Google Scholar
  28. P. P. Cook, “Rifampin and pyrazinamide for treatment of latent tuberculosis infection,” Clinical Infectious Diseases, vol. 42, no. 6, p. 892, 2006. View at Publisher · View at Google Scholar
  29. D. Schnappinger, S. Ehrt, M. I. Voskuil et al., “Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: insights into the phagosomal environment,” Journal of Experimental Medicine, vol. 198, no. 5, pp. 693–704, 2003. View at Publisher · View at Google Scholar
  30. L. M. Fu and T. M. Shinnick, “Genome-wide exploration of the drug action of capreomycin on Mycobacterium tuberculosis using Affymetrix oligonucleotide GeneChips,” Journal of Infection, vol. 54, no. 3, pp. 277–284, 2007. View at Publisher · View at Google Scholar
  31. Y. Zhang, “The magic bullets and tuberculosis drug targets,” Annual Review of Pharmacology and Toxicology, vol. 45, pp. 529–564, 2005. View at Publisher · View at Google Scholar
  32. J. D. McKinney, K. Honer Zu Bentrup, E. J. Munoz-Elias et al., “Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase,” Nature, vol. 406, no. 6797, pp. 735–738, 2000. View at Publisher · View at Google Scholar
  33. D. R. Sherman, M. Voskuil, D. Schnappinger, R. Liao, M. I. Harrell, and G. K. Schoolnik, “Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding α-crystallin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 13, pp. 7534–7539, 2001. View at Publisher · View at Google Scholar